Current Liabilities decreased faster than Benitec Biopharma Inc 's Cash & cash equivalent, this led to improvement in Benitec Biopharma Inc 's Quick Ratio to 325.45 a new company high.

Within Major Pharmaceutical Preparations industry Benitec Biopharma Inc booked the highest Quick Ratio than Benitec Biopharma Inc in the fourth quarter 2026. While Quick Ratio total ranking has improved so far during the Q4 2026 to 18, from total ranking in the third quarter 2026 at 58.

Explain Quick Ratio?
How much Cash & cash equivalents BNTC�s has?
What are BNTC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BNTC Quick Ratio	(Jun 30 2026) Q4	(Mar 31 2026) Q3	(Dec 31 2025) Q2	(Sep 30 2025) Q1	(Jun 30 2025) Q4
Y / Y Current Liabilities Change	-61.81 %	-50.99 %	-68.79 %	-58.66 %	-68.79 %
Y / Y Cash & cash equivalent Change	84.02 %	78.33 %	92.17 %	39.3 %	92.17 %
Quick Ratio MRQ	325.45	56.45	67.54	50.23	67.54
BNTC's Total Ranking	# 18	# 58	# 7	# 37	#
Seq. Current Liabilities Change	-83.11 %	126.1 %	-23.06 %	29.97 %	-78.32 %
Seq. Cash & cash equivalent Change	-2.62 %	88.98 %	3.45 %	-3.34 %	-5.63 %

Quick Ratio fourth quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 0
Healthcare Sector	# 0
Overall Market	# 18

Quick Ratio Statistics
High	Average	Low
325.45	23.06	0.63
(Jun 30 2026)		(Dec 31 2023)

Financial Statements
Benitec Biopharma Inc 's Current Liabilities	$ 1 Millions	Visit BNTC's Balance sheet
Benitec Biopharma Inc 's Cash & cash equivalent	$ 180 Millions	Visit BNTC's Balance sheet
Source of BNTC's Sales		Visit BNTC's Sales by Geography

Cumulative Benitec Biopharma Inc 's Quick Ratio

BNTC's Quick Ratio for the trailling 12 Months

BNTC Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-58.68 %	-60.75 %	-33.65 %	-11.79 %	4.41 %
Y / Y Cash & cash equivalent TTM Growth	73.99 %	73.79 %	114.22 %	156.12 %	242.64 %
Quick Ratio TTM	77.84	58.99	34.37	23.68	18.49
Total Ranking TTM	# 13	# 35	# 30	# 37	# 62
Seq. Current Liabilities TTM Growth	-11.12 %	-29.73 %	-21.79 %	-15.42 %	-15.56 %
Seq. Cash & cash equivalent TTM Growth	17.3 %	20.62 %	13.52 %	8.33 %	17.16 %

Quick ratio ranking by company, industry and sector >> Back to BNTC Financial Strength Comparisons >> Go to Compare BNTC Quick Ratio to its Competitors

On the trailing twelve months basis BNTC Cash & cash equivalent soared by 84.02 % in Q4 2026 year on year, while Current Liabilities dropped to $1 millions, this led to increase in in Benitec Biopharma Inc 's Quick Ratio to 77.84, above BNTC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 372 other companies have achieved higher Quick Ratio than Benitec Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2026 from 1905 to 2089.

Explain Quick Ratio?
How much Cash & cash equivalents BNTC�s has?
What are BNTC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 373
Healthcare Sector	# 694
Within the Market	# 18

trailing twelve months Quick Ratio Statistics
High	Average	Low
53.35	10.55	2.35
(Mar 31 2026)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Benitec Biopharma Inc	325.45	$ 179.972 Millions	$ 0.553 Millions
Mira Pharmaceuticals Inc	198.75	$ 8.113 Millions	$ 0.041 Millions
Veradermics Inc	139.85	$ 1,635.362 Millions	$ 11.694 Millions
Enliven Therapeutics Inc	116.86	$ 1,654.850 Millions	$ 14.161 Millions
Acrivon Therapeutics Inc	104.48	$ 89.959 Millions	$ 0.861 Millions
Arca Biopharma Inc	87.05	$ 2,225.581 Millions	$ 25.566 Millions
Tango Therapeutics Inc	82.19	$ 1,668.432 Millions	$ 20.299 Millions
Contineum Therapeutics Inc	70.25	$ 458.440 Millions	$ 6.526 Millions

Date modified: 2026-09-15T11:48:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.